Professeur Kim Dong-hyun of the Department of Ophthalmology at Korea University Anam Hospital and the research team of RudaCure Inc. (CEO: Yongho Kim) have demonstrated the pression intraoculaire-related safety of 'RCI001,' a novel treatment for inflammatoire ocular diseases.
In a recent animal study, Professeur Kim's research team administered a steroid formulation and RCI001 three times daily for five weeks, then compared pression intraoculaire and ocular surface status. While five weeks of RCI001 administration did not cause any elevation in pression intraoculaire or changes in the ocular surface, corticosteroid administration resulted in an approximately 38% increase in pression intraoculaire compared to baseline.
Professeur Kim a déclaré : "Steroid formulations have historically been difficult to use long-term in clinical practice due to the risk of complications," adding, "This study has shown that RCI001 holds promise as an effective long-term anti-inflammatoire agent for chronic ocular surface diseases requiring extended treatment, tels que sécheresse oculaire and Sjogren's syndrome, and I expect it to be of great benefit to patients à l'avenir."
This research was published in the October 2023 issue of the international academic journal Frontiers under the title 'Comparison of RCI001 and corticosteroid on the effects on pression intraoculaire in mice.'
Husaeng Ilbo: http://www.whosaeng.com/147434
Edaily: https://m.edaily.co.kr/news/read?newsId=02624006635774232&mediaCodeNo=257
Nate News: https://news.nate.com/view/20231018n12860?mid=n1101